Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graeme Semple

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Journal of Medicinal Chemistry|September 3, 2009
Design and evaluation of novel biphenyl sulfonamide derivatives with potent histamine H(3) receptor inverse agonist activityJonathan A Covel, Vincent J Santora, Jeffrey M Smith, et al.
Journal of Medicinal Chemistry|December 5, 2008
New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonistsChristopher M Yea, Christine E Allan, Doreen M Ashworth, et al.
Journal of Medicinal Chemistry|July 31, 2008
3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in miceGraeme Semple, Philip J Skinner, Tawfik Gharbaoui, et al.
Bioorganic & Medicinal Chemistry Letters|June 7, 2015
Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist seriesSangdon Han, Sanju Narayanan, Sun Hee Kim, et al.
Bioorganic & Medicinal Chemistry Letters|December 10, 2014
Discovery of 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamides as potent and selective CB2 receptor agonistsSangdon Han, Lars Thoresen, Xiuwen Zhu, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2007
Agonist lead identification for the high affinity niacin receptor GPR109aTawfik Gharbaoui, Philip J Skinner, Young-Jun Shin, et al.
Journal of Medicinal Chemistry|March 23, 2012
(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humansP Douglas Boatman, Brett Lauring, Thomas O Schrader, et al.
Journal of Medicinal Chemistry|January 11, 2017
Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial HypertensionThuy-Anh Tran, Bryan Kramer, Young-Jun Shin, et al.
ACS Medicinal Chemistry Letters|December 18, 2014
(7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acids as S1P1 Functional AntagonistsDaniel J Buzard, Luis Lopez, Jeanne Moody, et al.
Science Translational Medicine|August 24, 2012
Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppressionBrett Lauring, Andrew K P Taggart, James R Tata, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Journal of Medicinal Chemistry|September 3, 2009
Design and evaluation of novel biphenyl sulfonamide derivatives with potent histamine H(3) receptor inverse agonist activityJonathan A Covel, Vincent J Santora, Jeffrey M Smith, et al.
Journal of Medicinal Chemistry|December 5, 2008
New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonistsChristopher M Yea, Christine E Allan, Doreen M Ashworth, et al.
Journal of Medicinal Chemistry|July 31, 2008
3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in miceGraeme Semple, Philip J Skinner, Tawfik Gharbaoui, et al.
Bioorganic & Medicinal Chemistry Letters|June 7, 2015
Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist seriesSangdon Han, Sanju Narayanan, Sun Hee Kim, et al.
Bioorganic & Medicinal Chemistry Letters|December 10, 2014
Discovery of 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamides as potent and selective CB2 receptor agonistsSangdon Han, Lars Thoresen, Xiuwen Zhu, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2007
Agonist lead identification for the high affinity niacin receptor GPR109aTawfik Gharbaoui, Philip J Skinner, Young-Jun Shin, et al.
Journal of Medicinal Chemistry|March 23, 2012
(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humansP Douglas Boatman, Brett Lauring, Thomas O Schrader, et al.
Journal of Medicinal Chemistry|January 11, 2017
Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial HypertensionThuy-Anh Tran, Bryan Kramer, Young-Jun Shin, et al.
ACS Medicinal Chemistry Letters|December 18, 2014
(7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acids as S1P1 Functional AntagonistsDaniel J Buzard, Luis Lopez, Jeanne Moody, et al.
Science Translational Medicine|August 24, 2012
Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppressionBrett Lauring, Andrew K P Taggart, James R Tata, et al.
Pageof 6